Repligen Corporation (RGEN) Stock Score, Valuation & Financial Research
Repligen Corporation is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 33/100.
Quick answer for RGEN
Repligen Corporation currently has a Wall Street Score of 33/100. The stored market price is $174.73. Its financial score is 28/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Repligen Corporation does
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chr
RGEN financial snapshot
- Wall Street Score:
- 33/100
- Current price:
- $174.73
- Market capitalization:
- $9.86B
- Revenue:
- $763.3M
- Net income:
- $51.4M
- Free cash flow:
- $93.9M
- Cash:
- $582.6M
- Total debt:
- $687.6M
- EPS:
- 0.87
- P/E ratio:
- 200.8x
- Financial score:
- 28/100
- Valuation score:
- 0/100
- Revenue score:
- 14/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $93.9M, showing positive cash generation.
- The balance sheet shows $582.6M of cash versus $687.6M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 28/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research RGEN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.